Company / Capital Expenditures
ENANTA PHARMACEUTICALS INC Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$9.1M
FY2025
5-year range
$750.0K / $9.1M
FY2021-FY2025
Trend
+326.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures changed +326% YoY in FY2025, a notable deviation from the 9-year average annual change of +75%.
Based on SEC 10-K filings.
$9M in FY2025 with a 5-year CAGR of +24.9%.
Improved from $750,000 to $9M over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +84.4%
- 5-Year CAGR
- +24.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +24.9%, indicating consistent growth.
- In FY2025, capital expenditures increased 326.3% year-over-year.
- Lowest capital expenditures in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.1M | +326.3% |
| FY2024 | $2.1M | +183.3% |
| FY2023 | $750.0K | -48.1% |
| FY2022 | $1.4M | -73.3% |
| FY2021 | $5.4M | +81.7% |
| FY2020 | $3.0M | +19.0% |
| FY2019 | $2.5M | -47.1% |
| FY2018 | $4.7M | +102.8% |
| FY2017 | $2.3M | +127.2% |
| FY2016 | $1.0M | +69.6% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026